Strangvac is a novel vaccine used for the active immunisation of horses from five months of age.

Technologically advanced

Strangvac is a unique product that contains recombinant fusion proteins, which provide a broad, effective immune response¹. It does not contain live bacteria.

The antigens in Strangvac are extremely well conserved and Strangvac is expected to protect against all variants of Streptococcus equi².

All field strains examined to date had at least six identical antigens to the eight in Strangvac², while 98% of strains had none or only one amino acid variation relative to the 1,580 amino acids that make up the eight antigens in Strangvac².

Strangvac is currently the only European vaccine against strangles that can be administered intramuscularly.